Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Classifica tra le azioni #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Prezzo delle azioni
$0.11725176
Ultima sincronizzazione: 2025-07-14
Capitalizzazione di mercato
$481.50K
Variazione (1 giorno)
-0.20%
Variazione (1 anno)
0.00%
Paese
FR
Scambia PHAXIAM Therapeutics S.A. (PHXM)

Categoria

Storico del prezzo dell'azione per PHAXIAM Therapeutics S.A. (PHXM)
Prezzo di chiusura più alto: $0.12 il 2025-07-01

Prezzo di chiusura più basso: $130.13 il 2013-05-01
Storico del prezzo dell'azione di PHAXIAM Therapeutics S.A. dal 2013 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2025 -93.43%
2024 -61.15%
2023 -4.10%
2022 -78.67%
2021 -73.09%
2020 82.18%
2019 -31.14%
2018 -67.04%
2017 59.44%
2016 -51.03%
2015 -15.90%
2014 158.90%
2013 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$517.18 32.51%
US
$857.76 31.47%
NL
$735.86 7.74%
CH
$1.07K -6.40%
KR
$257.99 13.97%
BE